AlphaTON Capital (ATON) Q4 2025 earnings summary

Executive summary

• Net loss for fiscal year ended March 31, 2025 was $6.8 million, a significant decrease from $75.4 million in the prior year, mainly due to lower non-cash impairment charges.

• Operating expenses dropped to $7.4 million from $18.2 million year-over-year, reflecting reduced R&D and G&A costs.

• R&D expenses fell by 75% to $3.1 million, primarily due to paused clinical trial enrollment and program deprioritization.

• G&A expenses decreased by 24.9% to $4.3 million, driven by lower share-based compensation and professional fees.

Financial highlights

• Net loss for fiscal 2025 was $6.8 million, compared to $75.4 million in fiscal 2024.

• Cash and cash equivalents stood at $1.7 million as of March 31, 2025.

• Total current liabilities were $1.1 million at fiscal year-end.

• Basic and diluted loss per share was $5.72 for fiscal 2025, compared to $77.83 in fiscal 2024.

• Weighted average shares outstanding were 1,183 thousand for fiscal 2025.

Outlook and guidance

• Forward-looking statements highlight risks related to financing, going concern status, and scientific outcomes.

• Management cautions that actual results may differ materially from projections due to uncertainties.